The FRAME Toxicity Committee was set up in 1979 and produced its first report in 1983 (Balls et aI., 1983) , with the aim of promoting a revolution in attitudes toward toxicity testing. The FRAME Toxicity Committee produced its second report in 1990, for a discussion meeting at the Royal College of Physicians, in London, on 12-13 November (Balls et al., 1991) . What follows here are some of my personal assessments of what was and was not achieved during the 1980s and what needs to be done during the 1990s.
Positive signs and developments
(1) The concept of alternatives is now wklely accepted, by which is meant, in the context of animal experimentation: all procedures which can completely replace the need for animal experiments, reduce the numbers of animals required, or diminish the amount of pain or distress suffered by animals in meeting the essential needs of man and other animals. This is a Three Rs definition, because we can think in terms of reduction alternatives, refinement alternatives and replacement alternatives.
(2) We have new laws on animal experimentation, in the EC, in some of its Member States, and elsewhere. Directive 86/609/EEC (Anon, 1986) is clearly a Three Rs law, since Article 7 states: 7.2: An experiment shall not be performed if another scientifically satisfactory method of obtaining the result sought, not entailing the use of an animal, is reasonably and practicably available. 7.3: When an experiment has to be performed, the choice of species shall be carefully considered and, where necessary, explained to the authority. In a choice between experiments, those which use the minimum number of animals, involve animals with the lowest degree of neurophysiological sensitivity, cause the least pain, suffering, distress or lasting harm and which are most likely to provide satisfactory results shall be selected.
Similarly, the UK Animals (Scientific Procedures) Act 1986 requires that:
The Secretary of State shall not grant a project licence unless he is satisfied that the applicant has given adequate consideration to the feasibility of achieving the purpose of the programme to be specified in licence by means not involving the use of protected animals. and is based on a 1985 Government White Paper (Anon, 1985) which states that:
Animal experiments that are unnecessary, use unnecessarily large numbers of animals, or are unnecessarily painful are indefensible.
(3) The legislation also contains powerful clauses concerning the justification for carrying out any animal experiments at all. Directive 86/609/EEC states: 12.2: Where it is planned to subject an animal to an experiment in which it will, or may, experience severe pain which is likely to be prolonged, that experiment must be specifically declared and justified to, or specifically authorized by, the authority. The authority shall take appropriate judicial or administrative action if it is not satisfied that the experiment is of sufficient importance for meeting the essential needs of man or animal. and 7.4: All experiments shall be designed to avoid distress and unnecessary pain and suffering to the experimental animals.
While the UK law requires that:
In determining whether and on what terms to grant a project licence the Secretary of State shall weigh the likely adverse effects on the animals concerned against the benefit likely to accrue as a result of the programme to be specified in the licence.
(4) Much excellent work is being carried out on reconsidering toxicity testing procedures -for 199 example, by ECETOC working parties (e.g. ECETOC, 1988) , and by scientific societies, such as the British Toxicology Society, which has made recommendations about hierarchical procedures for eye irritancy and skin irritancy. In addition, a great deal of important fundamental work is in progress on replacement alternatives and their strategic use. The replacement alternatives include: (i) the improved storage, exchange and use of information, so that the unnecessary repetition of experiments on animals can be avoided;
(ii) the use of physical and chemical techniques and predictions based on the physical and chemical properties of molecules; (iii) mathematical modelling of quantitative structure-activity relationships (QSAR); (iv) molecular modelling and the use of computer graphics to design in desired properties and design out features likely to cause toxic effects;
(v) mathematical modelling of biochemical, physiological, pharmacological and toxicological systems and processes, so that the fate and effects of substances in the body dm be predicted; (vi) the use of lower organisms not protected by legislation controlling animal experimentation, including invertebrates, plants and microorganisms; (vii) the use of embryonic and larval vertebrates before they reach the developmental stage at which they become 'protected' vertebrates;
(viii) the use of in vitro methods, including: sub-cellular fractions; the short-term maintenance of perfused organs, tissue slices and cell suspensions; and tissue culture proper (i.e. cell and organotypic cultures); (ix) human studies, including epidemiology, post-marketing surveillance, and the properlyregulated use of human volunteers.
(5) Non-animal methods are now widely used in screening candidate compounds and formulations, and as adjuncts to animal procedures, and there are high hopes (indeed, high expectations) that genuine replacements will be developed, validated and accepted in the near future. For example, the following methods are in the process of development and validation as alternatives to the Draize eye irritancy test:
(a) the enucleated superperfused eye method (b) the mouse eye permeability test (c) the bovine corneal cup method (d) the bovine corneal opacity method (e) the corneal plasminogen activator method (f) the rabbit corneal epithelium wound healing assay (g) the chicken chorio-allantoic membrane (CAM) test (h) the hen's egg test (HET) (i) various cytoxicity tests, including tests for: neutral red uptake; neutral red release (developed by a FRAME research group); increase in total protein (e.g. the FRAME kenacid blue method); uridine uptake; membrane integrity; cell viability (j) the EYTEX™ protein denaturation method Negative signs and clouds on the horizon (1) The revolution in thinking in toxicology and toxicity testing which we sought in 1982 has not yet happened. The 'check-list' approach to toxicity testing is still firmly in place. As Gerhard Zbinden put it in a recent editorial (Zbinden, 1988) , the more authoritative the regulatory guidelines, the better for the industrial toxicologist, who tends to think as follows:
The hundreds of other ways that could be devised to study the safety of new compounds may provide a stimulating intellectual exercise and lead to illuminating scientific discoveries, but if my snooping around the boundaries of standard toxicological practice provides findings that are unexplained or not acceptable to regulatory agencies, the development of a new drug may be greatly retarded and occasionally even aborted. So if I want to keep my job, I am better off doing toxicology their way and forgetting about creativity. And if I hope to market my drug on a worldwide basis, I am going to use the guidelines that are the most demanding with regard to numbers of species, subjects and dose levels, and duration of treatment. I can be sure that no regulatory agency will object to a toxicological dossier that is more voluminous Balls than the one it might consider desirable or necessary.
(2) Animal welfare is not sufficiently taken into account. Again, as Zbinden (1988) put it:
Many of the toxicological test procedures inflict substantial pain and anxiety on the laboratory animals. This is particularly true for animals used in acute toxicity studies, and those included in the high dose groups of repeated-dose experiments. Considerable suffering must be assumed in animals bearing large tumors or afflicted with organ damage, e.g. perforated gastrointestinal ulcers, myocardial infarctions, liver necrosis and muscle wasting. Functional disturbances such as paralysis, excessive central nervous system stimulation, diarrhea, polyuria, hypotension and sensory organ disfunction cause stress and anxiety. Repeated injections often induce considerable local pain, and animals sometimes struggle desperately to avoid another injection. Topical administration of irritant and corrosive substances to the skin and mucous membranes is a painful procedure that has come under particularly heavy criticism by animal welfare advocates ....
A look at regulatory guidelines for safety studies shows that they are essentially silent on the animal welfare issues. A notable exception is the proposed revision of the DECD Guideline for Testing of Chemicals 401, Acute Oral Toxicity of April II, 1986. It includes the following statement: 'Animals showing severe and enduring signs of distress and pain may need to be humanely killed. Doses known to cause marked pain and distress, due to corrosive or severely irritant actions, need not be administered, even when no mortality has been observed at tolerated doses.'
(3) Demands for greater safety for workers and for consumers, and for greater protection of the environment, are leading to demands for more toxicity testing-e.g.
as a basis for reconsideration of th~safety of pesticides which have been in use for some time; for establishing the potential hazard or otherwise of existing industrial chemicals (i.e. chemicals in use before regulations on new chemicals came into force); and for assessing the safety or otherwise of cosmetic ingredients and formulations. Unfortunately, there are signs of completely unrealistic attitudes (1990). tThese estimates were added by FRAME and published in FRAME News (Anon, 1990a) .
about the economic and political impact of proposals to introduce new or modified regulatory guidelines. For example, Dr lain Purchase of the CTL at ICI has calculated that it would cost more than ECU 8· 5 billion to do baseline studies on the 12860 existing chemicals listed by the US National Research Council as produced at greater than 450 tonnes per annum. For a table (Table 1 ) publiShed in FRAME News (Anon, I990a), it was calculated that such testing would require nearly 11 million animals! Similarly, proposals currently under discussion in the EC Commission on amending Directive 76/768/EEC on cosmetics testing are equally unrealistic. It has been calculated that to do baseline studies on only 3000 of the 6000-8000 cosmetics ingredients thought to be currently in use in Europe would cost in the order of ECU 1. 8 billion and would require about 2 million animals (Anon, I990b). Testing on this scale would be logistically impossible, economically unsupportable and politically unacceptable, yet this is a logical interpretation of the proposals! (4) Except, perhaps, in relation to long-term animal studies on pharmaceuticals, little progress is being made toward the harmonization of regulatory guidelines.
(5) Finally, there has been a general failure to face up to the fact that laboratory animals are only 'models' for man, so their usefulness is strictly limited, and their relevance and reliability has constantly to be questioned and assessed. At most, animal toxicity tests can provide a basis for making predictions and judgements-thec annot tell us what will actually happen in man.
Challenging the legality of toxicity testing
The new laws on animal experimentation, such as the EC Directive and the UK Act, recognize that animal experimentation can be justified for certain reasons. For example, a resolution related to Directive 86/609/EEC states that:
Member States undertake not to permit the use of animals in experiments except for the following purposes: (a) (i) the avoidance or prevention of disease, iIlhealth or other abnormality, or their effects, in man, vertebrate or invertebrate animals or plants, including the production and the quality, effectiveness and safety testing of drugs, substances or products;
(ii) the diagnosis or treatment of disease, ill-health or other abnormality, or their effects, in man, vertebrate or invertebrate animals or plants; (b) the assessment, detection, regulation or modification of physiological conditions in man, vertebrate and invertebrate animals or plants; (c) the protection of the natural environment in the interests of the health or welfare of man or animal; This kind of statement is being used to justify toxicity testing, and the mere existence of regulatory guidelines and the insistence of individual regulators that particular types of data be provided are being used to overcome all the noble principles laid down in other parts of these laws.
This must be questioned, and, again, I turn to Zbinden (1988) for support:
A common feature of many new animal protection laws is the requirement to demonstrate the advisability, in some countries even the unconditional necessity, of all proposed animal experiments. It is probable that those reviewing applications for toxicological studies will expect more justification for an animal experiment than the simple statement that the proposed test is necessary because it is required by a regulatory guideline. In particular, permission to conduct a toxicological experiment will not easily be obtained if the country in which the study will be conducted does not require the proposed test, or is satisfied with an experiment involving fewer animals or a shorter duration of treatment. Thus, the easy way out described above, i.e. to conduct toxicity studies always according to the most demanding national guidelines, will, in future, often not be possible.
The impression must not be given that the controls on animal experimentation are in some way subordinate to regulatory guidelines. In particular, I question whether the check-list approach to toxicity testing can any longer be considered to be other than an illegal practice. Toxicity tests should be justified on the grounds of specific need, not general principles (and especially general principles with a dubious basis).
The LDSO: a crucial test-case
With regard to the LD50, recent moves within Balls the Ee, especially in relation to the Fixed Dose Procedure originally proposed by the British Toxicology Society, are to be welcomed and encouraged, but they are not enough. In particular, it is astounding that the classical LD50 test is stiII being performed, and, if it is going to take as long to replace other tests as it is taking to replace the classical LD50, what hope is there of achieving the essential balance between human need and animal welfare in the short-term and of replacing animal tests altogether in the longer term?
There is only one acceptable alternative to doing the classical LDSO test (by which I mean the use of large numbers of animals of both sexes at many dose levels in order to obtain a 'precise' LD50 value)-and that is to stop doing it. Its use as a basis for the classification of chemicals is unscientific, because the degree of precision it purports to give is an unobtainable illusion, largely because of the effects of uncontrollable biological variables. It is also unnecessary, because LD50 values are used to place chemicals in one of a small number of broad categories of toxicity and, worse, various regulatory authorities define these categories differently! Why then, is it still performed? The answer is because some toxicologists like doing it, some lawyers within industrial companies demand it, and some regulators, whatever the public stance of their countries or their regulatory bodies, require it.
If such a practice is unscientific and unnecessary, it cannot possibly be legal under the terms of various national or international laws.
A moratorium on the performance of the classical LD50 test should be declared-now!
It is often said that the LDSO test (in whatever form) is not synonymous with acute toxicity testing, which provides essential evidence on which the assessment of risks to human beings and other animals is based. Lethality as an endpoint, although definite and incontrovertible, is crude and causes much suffering.
Reduction in the numbers of animals involved can be achieved by using an approximate LDSO test, the up-and-down method or other stepwise procedures, and applying a limit on the highest dose applied can afford a degree of refinement.
The Fixed Dose Procedure has come successfully through two national and international validation trials, so there should be no reason, on scientific, ethical or political grounds, for not accepting it as a basis for the classification of chemicals.
Looking beyond the current debate, what is the prospect for classifying chemicals (and achieving the other purposes of acute toxicity tests) without using animals at all?
The way forward is to work toward the integrated use of the following: 1. data banks-to consider the known properties of related chemicals and their effects in animals and in man 2. predictive QSAR models 3. mathematical toxicokinetic models 4. in vitro toxicokinetic tests 5. in vitro cytotoxicity tests 6. in vitro target organ toxicity tests.
The FRAME Research Groups at the University of Nottingham Medical School are heavily involved in the development of in vitro cytotoxicity tests and in their use in estimating potential toxic hazard, including irritancy and intrinsic toxicity. Up to now, much of our work has involved retrospective predictions-that is, evaluating the usefulness of the results we obtain in comparison with what is already known from previous animal experiments or human experience. For many types of chemical in vivo/in vitro correlations are very good, and there are early indications from tests on a small number of chemicals (in collaboration with Bjorn Ekwall and his colleagues in the Scandinavian MEIC validation scheme) that the correlation between human lethal concentrations and in vitro cytotoxic values is at least as good as that between human and rodent lethal doses (Ekwall et al., 1989 ).
An eight-point plan for replacing the LD50
At the EC Seminar on the LD50 held in Brussels last September, I proposed the following (Balls, 1990) : 203
A ban on performance of the classical LD50
test or any test more rigorous than that specified in the 1987 OECD Guideline. 2. An early end to the use of death as an endpoint in acute toxicity tests. 3. Acceptance of the Fixed Dose Procedure. 4. Willingness by regulatory authorities to accept any well-designed and appropriate acute toxicity study. 5. The rationalization and harmonization of regulatory guidelines and classification schemes. 6. The greater encouragement and financial support of the development, validation and use of computer models and in vitro systems in toxicity testing. 7. The establishment of a scheme for recording, assessing, expressing and making available data from past acute toxicity tests in animals and acute exposure in humans, as a basis for the validation and evaluation of alternative methods and strategies. 8. The development of effective procedures for the more-rapid international evaluation and regulatory and legal acceptance of new and scientifically-validated testing strategies, including those not involving animal tests. These proposals were in line with views expressed by other participants in the Seminar, who unanimously resolved to agree that total replacement of the use of animals is a desirable long-term objective.
Short-term and long-term objectives
Confusion about goals can be a source of difficulties and misunderstandings, as members of regulatory agencies are dealing with current submissions, industrial toxicologists are planning tests to be carried out in the near future, and in vitro toxicologists and computer modellers are planning the replacement alternative strategies for the more distant future.
Reducing the numbers of animals used in toxicity tests, and refining the procedure used so that suffering in minimized, are shortterm goals. Genuine replacement will be harder to achieve.
Meanwhile, the rationalization (not the mere harmonization) of regulatory guidelines deserves a high priority. However, most of all, toxicologists and others need to face up to the real challenge before them -to see a world full of specific problems needing individually tailored solutions, rather than common problems which can be solved by slavish adherence to standardized guidelines.
The inescapable significance of validation
Those of us involved in the development of nonanimal methods and strategies also have a duty to be realistic. In particular, before any nonanimal method or battery of methods can be a serious candidate for use as a genuine replacement alternative in the prospective identification of potential hazard, it must be subjected to the rigors of the validation process. We have recently given this important term a comprehensive definition (Balls & Clothier, 1989) :
Validation is an evolutionary process, whereby in vitro methods, properly developed in the laboratory of origin, are independently assessed for their reliability, reproducibility and interlaboratory transferability, before being evaluated in competition with other non-animal methods for their acceptability for integration with (and, wherever possible, as replacements for) conventional animal toxicity tests and strategies in providing relevant information of high scientific quality for use in assessing the potential toxicological hazard and/or safety of chemical compounds, formulations and other agents, to which human beings, other animals, other living organisms, and the environment in general, might be exposed.
There is also widespread agreement among those involved in the search for non-animal tests that validation must involve the following stages:
1. Intralaboratory validation: design of the original basic procedure, followed by a study with a small set of model chemicals, followed by a consolidation phase, in which all previous decisions are challenged, so that a sound protocol can be derived and pu blished in a form suitable for transfer to other laboratories.
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Interlaboratory validation: examination of
the scientific quality of the new test protocol when used in other laboratories, including its reliability and reproducibility in predicting the effects of a large number of chemicals with different degrees of toxicity; interlaboratory validation should also involve a blind trial with at least 50 chemicals, with independent assessment and publication of the results obtained.
Extralaboratory validation: assessment, in
competition with other methods, for potential usefulness in providing data relevant to realworld problems, feasibility in terms of cost and test chemical throughput, and value as part of an alternative test or alternative/ animal test battery.
Regulatory and legal validation:
the replacement of any conventional animal procedure by a non-animal test or a battery of tests will require that it must be acceptable to one or more regulatory agencies and legal authorities.
Many in vitro tests are now in the second stage of this sequence, and some are in the third. New animal test procedures should also be validated. For example, the Fixed Dose Procedure is now passing from the third to the fourth stagehopefully, at least one regulatory authority will soon declare it acceptable. , Two significant developments'took place in 1990. First, a workshop on scientific aspects of validation, jointly organized by the Center for Alternatives to Animal Testing (Johns Hopkins University) and the European Research Group for Alternatives to Animal Testing (ERGATT), was held in Amden, Switzerland, in January. Its report and recommendations have been published and will, we hope, lay down criteria and standards for future validation studies (Balls et al., 1990a) .
Secondly, a workshop organized by ERGAIT and financially supported by the EC, was held near Athens in April, to consider the principles involved in promoting the regulatory and legal acceptance of validated non-animal methods and strategies. It is hoped that the report of this workshop will also come to be viewed as a crucial development in the evolution of replacement alternati ves (Balls et al., 1990b) .
A time for patience or insistence? In a comment in a recent issue of TIPS, Gerhard Zbinden (1990) referred to an editorial recently published in the Neue Zurcher Zeitung and entitled 'Wieviel Ungeduld braucht der Tierschutz?' (How much impatience do animal protectionists need?) The writer expressed surprise that agitation against biomedical experiments is increasing at a time when many countries have passed far-reaching animal protection legislation, when many bodies have issued ethical guidelines, and when the number of animals used is decreasing substantially and steadily.
Zbinden goes on to express his own surprise that there is impatience about an apparent failure to use replacement alternatives, when it is evident that the use of in vitro methods is increasing rapidly. In a sense, he himself provides the explanation -most scientists who turn to in vitro systems do so, not because they are 'alternatives', but because they are the best way of tackling the problems at hand. Also, non-animal methods have not yet been developed, scientifically validated and independently evaluated to the point where they could be put to the regulatory agencies as genuine replacements for the currentlyaccepted animal tests.
It is not difficult to counter the line of argument of the editorial writer in the Neue Ziircher Zeitung-the new animal protection laws undoubtedly have great potential, but their References Anon (1985) actual effects will depend on how forcefully they are implemented. Ethical guidelines are only guidelines, and are unlikely ever to achieve the status of requirements, which has been achieved by many of the regulatory 'guidelines'. This is no time to relax the pressure, to allow those who advocate the indefinite use of animal models in biomedical research and testing to think that their problem is solved. As a recent A TLA editorial (Anon, 1989) concluded: 'Members of the moderate animal welfare movement must make it clear to toxicologists (and others) that they will not allow them to settle for less (than the ultimate goal of total replacement). '
The line taken in the Neue Ziircher Zeitung is also typical of subtle attempts to divide the Three Rs approach -'The new laws, guidelines and attitudes are leading to reduction and refinement, so why not settle for that?', they seem to say. That temptation must also be resisted, for it is our experience that there is much to be gained by working with others who share our commitment to the Three Rs, but whose particular strategies complement our own. This is an appropriate moment to reconfirm our additional commitment to the indivisible three parts of the same whole, the Three Rs of Russell & Burch (1959)-reduction, refinement and replacement. Hence, while I applaud the initiative taken by the BTS and the Ee in relation to the LD50 and the FOP, I have to conclude that modification of the L050 test, however worthwhile, will not be enough. Anon (1990a) 
